Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark; Pharmaceutical R&D, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Roche Pharmaceutical Research & Early Development, Pre-Clinical CMC, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Eur J Pharm Sci. 2024 Mar 1;194:106703. doi: 10.1016/j.ejps.2024.106703. Epub 2024 Jan 14.
Predicting the absorption of drugs from enabling formulations is still challenging due to the limited capabilities of standard physiologically based biopharmaceutics models (PBBMs) to capture complex absorption processes. Amongst others, it is often assumed that both, molecularly and apparently dissolved drug in the gastrointestinal lumen are prone to absorption. A recently introduced method for measuring concentrations of molecularly dissolved drug in a dynamic in vitro dissolution setup using microdialysis has opened new opportunities to test this hypothesis and refine mechanistic PBBM approaches. In the present study, we compared results of PBBMs that used either molecularly or apparently dissolved concentrations in the simulated gastrointestinal lumen as input parameters. The in vitro dissolution data from three supersaturating formulations of Posaconazole (PCZ) were used as model input. The modeling outcome was verified using PCZ concentration vs. time profiles measured in human intestinal aspirates and in the blood plasma. When using apparently dissolved drug concentrations (i.e., the sum of colloid-associated and molecularly dissolved drug) the simulated systemic plasma exposures were overpredicted, most pronouncedly with the ASD-based tablet. However, if the concentrations of molecularly dissolved drug were used as input values, the PBBM resulted in accurate prediction of systemic exposures for all three PCZ formulations. The present study impressively demonstrated the value of considering molecularly dissolved drug concentrations as input value for PBBMs of supersaturating drug formulations.
由于标准生理相关生物药剂学模型 (PBBM) 捕捉复杂吸收过程的能力有限,预测赋形剂药物的吸收仍然具有挑战性。其中,通常假设胃肠道腔中分子和表观溶解的药物都容易被吸收。最近引入了一种使用微透析在动态体外溶解装置中测量分子溶解药物浓度的方法,为测试这一假设和改进机制 PBBM 方法提供了新的机会。在本研究中,我们比较了使用模拟胃肠道腔中分子溶解或表观溶解浓度作为输入参数的 PBBM 的结果。将泊沙康唑 (PCZ) 三种超饱和制剂的体外溶解数据用作模型输入。使用人肠抽吸物和血浆中测量的 PCZ 浓度随时间的变化来验证模型结果。当使用表观溶解药物浓度(即胶体结合和分子溶解药物的总和)时,模拟的全身血浆暴露被高估,基于 ASD 的片剂最为明显。然而,如果使用分子溶解药物的浓度作为输入值,则 PBBM 可以准确预测所有三种 PCZ 制剂的全身暴露。本研究令人印象深刻地证明了将分子溶解药物浓度作为超饱和药物制剂 PBBM 的输入值的价值。